Form 8-K · Current report
Altria 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000764180
- Accession no.
- 0000764180-26-000112
Summary
Altria Group reported 2026 third-quarter and nine-month results, with third-quarter adjusted diluted EPS up 4.8%, and raised its 2026 full-year adjusted diluted EPS guidance to $5.66–$5.74. The company's board authorized a $1 billion expansion of its share repurchase program, and Altria said Helix expanded its on! PLUS portfolio with new flavors.
Key points
- Altria reported third-quarter 2026 net revenues of $6.132 billion, up 1.0%, and adjusted diluted EPS of $1.52, up 4.8%.
- Altria's board authorized a $1 billion expansion of its existing share repurchase program, which expires December 31, 2027.
- Altria raised its 2026 full-year adjusted diluted EPS guidance to $5.66–$5.74, representing 4.5%–6.0% growth from $5.42 in 2025.
- Helix expanded the on! PLUS portfolio with Blueberry Mint and Mango Pineapple flavors across 6-, 9-, and 12-milligram nicotine strengths.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On October 29, 2026, Altria Group, Inc. (“Altria”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference in this Item 2.02. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.